PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
4.69%
Revenue growth exceeding 1.5x Medical - Pharmaceuticals median of 1.02%. Joel Greenblatt would investigate if growth quality matches quantity.
5.49%
Cost growth exceeding 1.5x Medical - Pharmaceuticals median of 0.20%. Jim Chanos would check for structural cost disadvantages.
1.43%
Gross profit growth 50-75% of Medical - Pharmaceuticals median of 2.84%. Guy Spier would scrutinize competitive position.
-3.11%
Margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate competitive position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3.72%
Other expenses reduction while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate advantages.
1.10%
Operating expenses growth below 50% of Medical - Pharmaceuticals median of 3.83%. Joel Greenblatt would investigate efficiency.
4.77%
Total costs growth near Medical - Pharmaceuticals median of 4.37%. Charlie Munger would verify industry norms.
17.39%
Interest expense change of 17.39% versus flat Medical - Pharmaceuticals costs. Walter Schloss would verify control.
-3.38%
D&A reduction while Medical - Pharmaceuticals median is 3.25%. Seth Klarman would investigate efficiency.
10.35%
EBITDA growth exceeding 1.5x Medical - Pharmaceuticals median of 2.03%. Joel Greenblatt would investigate advantages.
5.41%
Margin change of 5.41% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
2.77%
Operating income growth exceeding 1.5x Medical - Pharmaceuticals median of 1.74%. Joel Greenblatt would investigate advantages.
-1.84%
Operating margin decline while Medical - Pharmaceuticals median is 0.00%. Seth Klarman would investigate causes.
76.47%
Other expenses change of 76.47% versus flat Medical - Pharmaceuticals. Walter Schloss would verify control.
10.32%
Pre-tax income growth while Medical - Pharmaceuticals declines. Peter Lynch would examine advantages.
5.38%
Margin change of 5.38% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
9.71%
Tax expense change of 9.71% versus flat Medical - Pharmaceuticals. Walter Schloss would verify strategy.
10.77%
Net income growth exceeding 1.5x Medical - Pharmaceuticals median of 1.29%. Joel Greenblatt would investigate advantages.
5.81%
Margin change of 5.81% versus flat Medical - Pharmaceuticals. Walter Schloss would verify quality.
10.76%
EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 4.80%. Joel Greenblatt would investigate advantages.
10.76%
Diluted EPS growth exceeding 1.5x Medical - Pharmaceuticals median of 4.82%. Joel Greenblatt would investigate advantages.
-0.00%
Share count reduction while Medical - Pharmaceuticals median is 0.54%. Seth Klarman would investigate strategy.
-0.00%
Diluted share reduction while Medical - Pharmaceuticals median is 0.47%. Seth Klarman would investigate strategy.